• 1
    Garthwaite SM, McMahon EG. The evolution of aldosterone antagonists. Mol Cell Endocrinol 2004; 217: 2731.
  • 2
    Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Polycystic Ovary Syndrome, eds DunaifA, GivensJR, HaseltineF. Boston, MA: Blackwell Scientific, 1992; 37784.
  • 3
    Searafini P, Lobo RA. The effects of spironolactone on adrenal steroidogenesis in hirsute women. Fertil Steril 1985; 44: 5959.
  • 4
    Milewicz A, Silber D, Kirschner M. Therapeutic effects of spironolactone in polycystic ovary syndrome. Obstet Gynecol 1983; 61: 42932.
  • 5
    Falch DK, Schreiner A. The effect of spironolactone on lipid, glucose and uric acid levels in blood during long-term administration to hypertensives. Acta Med Scand 1983; 213: 2730.
  • 6
    Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, DeVries C, Plouin PF, Corvol P, Menard J. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987; 60: 8205.
  • 7
    Zulian E, Sartorato P, Benedini S, Baro G, Armanini D, Mantero F, Scaroni C. Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile. J Endocrinol Invest 2005; 28: 4953.
  • 8
    Satoh T, Itoh S, Seki T, Itoh S, Nomura N, Yoshizawa I. On the inhibitory action of 29 drugs having side effect gynecomastia on estrogen production. J Steroid Biochem Mol Biol 2002; 82: 20916.
  • 9
    Fernandes CE, Pompei LM, Machado RB, Ferreira JA, Melo NR, Peixoto S. Effects of estradiol and norethisterone on lipids, insulin resistance and carotid flow. Maturitas 2008; 59: 24958.
  • 10
    Scherstén B, Thulin T, Kuylenstierna J, Engström M, Karlberg BE, Tolagen K, Nordlander S, Nilsson G. Clinical and biochemical effects of spironolactone administered once daily in primary hypertension. Multicenter Sweden study. Hypertension 1980; 2: 6729.
  • 11
    Ames RP, Peacock PB. Serum cholesterol during treatment of hypertension with diuretic drugs. Arch Intern Med 1984; 144: 7104.
  • 12
    Wild RA, Demers LM, Applebaum-Bowden D, Lenker R. Hirsutism: metabolic effects of two commonly used oral contraceptives and spironolactone. Contraception 1991; 44: 11324.
  • 13
    Garcá Puig J, Miranda ME, Mateos F, Herrero E, Lavilla P, Gil A. Hydrochlorothiazide versus spironolactone: long-term metabolic modifications in patients with essential hypertension. J Clin Pharmacol 1991; 31: 45561.
  • 14
    Gökmen O, Senöz S, Gülekli B, Işik AZ. Comparison of four different treatment regimes in hirsutism related to polycystic ovary syndrome. Gynecol Endocrinol 1996; 10: 24955.
  • 15
    Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 70917.